Daily PubMed evidence board
Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
This systematic review and meta-analysis pooled data from interventional trials and observational studies of adults with locally advanced or metastatic ur…
Signal score70Research triage score
CertaintyModerateVerify in full text
PMID42223943Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This systematic review and meta-analysis pooled data from interventional trials and observational studies of adults with locally advanced or metastatic urothelial carcinoma treated with antibody-drug conjugates (ADCs): enfortumab vedotin, disitamab vedotin, and sacituzumab govitecan. The authors found that enfortumab vedotin monotherapy had an objective response rate (ORR) around 44% in both trial and observational settings. Combining enfortumab vedotin with pembrolizumab had higher response rates (~67% in trials; ~65% in cisplatin-ineligible patients). Disitamab vedotin combined with PD-1 inhibitors showed high activity in trials (ORR ~75%) though observational cohorts reported lower ORR (~62%). Meta-regression indicated prior PD-1/L1 exposure and higher hepatic tumor burden were associated with lower responses. The results suggest ADC-based regimens show substantial activity in la/mUC, but full-text review is needed to evaluate durability of benefit, harms, and applicability to specific patients.
Why it matters
- Addresses treatment outcomes for adults with locally advanced or metastatic urothelial carcinoma (la/mUC), a population with high unmet need.
- Compares real-world and trial evidence for three ADCs in common use (enfortumab vedotin, disitamab vedotin, sacituzumab govitecan), which can inform therapeutic positioning and guideline updates.
- Identifies clinical covariates (prior PD-1/L1 exposure, hepatic tumor burden) associated with attenuated responses, relevant for patient selection and sequencing decisions.
Primary outcomes
- Disease control rate
- Objective response rate (ORR)
- Clinical complete response
Effect summary
Abstract-reported pooled estimates: enfortumab vedotin monotherapy ORR ~43.9% (interventional) and ~44.6% (observational). Enfortumab vedotin plus pembrolizumab ORR ~67.5% overall in interventional cohorts and ~65.4% in cisplatin-ineligible patients. Disitamab vedotin plus PD-1 inhibitors ORR ~74.7% in interventional trials and ~61.7% observationally. Meta-regression found prior PD-1/L1 exposure (β = -0.071; P = .003) and hepatic tumor burden associated with reduced responses.
Benefit-cost lens
| Quick take | This meta-analysis provides pooled response estimates for ADC regimens in la/mUC that could change prioritization or trial design; however, benefit-cost claims require local cost, survival/quality-of-life effects, and target-population prevalence before implementation. |
|---|---|
| BCR anchor | 2 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Assessment based on PubMed metadata and abstract only; full text needed to confirm endpoints, time-to-event data, harms, and cost-relevant inputs. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | rapid-abstract-screen |
|---|---|
| Verdict | Some concerns |
| Notes | Assessment based only on PubMed metadata and abstract. Although the study is a systematic review and NMA with many included studies, risks include potential heterogeneity across interventional and observational data, reconstructed individual patient data methods, and absence of abstract-level details on outcome definitions, censoring, and adverse events. Full-text evaluation needed for formal risk-of-bias appraisal. |
Harms, equity, conflicts & implementation
| Implementation | Full-text review, extraction of survival and safety data, assessment of durability of responses, local cost and capacity analysis (drug procurement, infusion, toxicity management), and multidisciplinary clinical review before changing practice or policy. |
|---|---|
| Equity impact | Unclear from abstract. Potential access issues (cost, specialist infusion capacity) and differential prior-immunotherapy exposure could exacerbate inequities; subgroup data in full text needed. |
| Harms | Harms and adverse-event profiles are not detailed in the abstract and require full-text confirmation; ADCs and combinations with immunotherapy have known toxicity risks that must be assessed before implementation. |
| Replication | Unknown from automated PubMed triage; replication would require reanalysis of included studies and access to reconstructed patient-level data. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.